Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf
of Heron Therapeutics, Inc. (“Heron Therapeutics” or the
“Company”) (NASDAQ: HRTX)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
If you are a shareholder who suffered a loss, click here to
participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
On May 1, 2019, the Company confirmed receipt of a Complete Response
Letter from the FDA in which the FDA was unable to approve the Company’s
New Drug Application for a new postoperative pain medication it had been
developing, due to the need for additional information.
On this news, shares of Heron Therapeutics fell $3.93 per share, or over
18%, to close at $17.75 on May 1, 2019, thereby injuring investors.
If you purchased Heron Therapeutics securities, have information, or
would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park
East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at
888-773-9224, or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number, and the number of shares purchased.mayb
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605006005/en/
Copyright Business Wire 2019